NanoViricides, Inc. (stock symbol: NNVC.OB) is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. Utilizing nanoscale materials and processes licensed from TheraCour Pharma, Inc., we are developing anti-viral drugs against a wide range range of human and animal viruses.

NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.

NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.

 
Click here to see the Effect of Nanoviricide Treatment on EKC (Epidemic Kerato-Conjunctivitis)
 
Click here to download the NanoViricides, Inc. 2007 Calendar Year Summary by the CEO, Dr. Eugene Seymour [pdf]
 
Click here to read the nanomedicine chapter from Jain BioPharma's market report on antivirals
 
Click here for news about NanoViricides' move to NASD's OTC Bulletin Board
 
Click here to see Nanoviricides Dismantling a Virus